UK: Mapping Out the Future of Regulatory Pharmacogenetics

Last Updated: 16 September 2005
Article by Neil C Trueman

Pharmacogenetics is the name given to the study of inter-individual variations in our DNA and how these can affect our individual responses to pharmaceutical drugs. A more individualised understanding of how drugs affect different people has the potential to promise a future of personalised medicine based on an analysis of our individual genotype where toxic side effects of drugs are greatly reduced and drugs even have a guarantee of efficacy. This article aims to summarise the current status of pharmacogenetics within the EMEA from a regulatory perspective.

Introduction

It remains a startling fact to most of us that a pharmaceutical that is regarded as a breakthrough leading treatment may in fact be effective in perhaps half the population of the people it is prescribed to. Whilst the popular press would have us believe that the latest drug is the next ‘magic bullet’ treatment for everyone with the relevant indication, the reality of variable efficacy between individuals has been known to the medical establishment for decades.

In fact, the inter-individual variations in our responses to drugs are as variable as the inter individual variations in, say, our eye and hair colour – much of it boils down to our inherited genotype. Whilst inherited variations in eye colour may not affect the way we see, differences in DNA (genotype) may result in significant changes to functional proteins. Typically these might be receptors for drugs, transporter proteins that move drugs and other substances through our cell walls, or the metabolic enzymes that convert the drugs we take into something our bodies can eventually excrete.

Genetic variations between individuals clearly present a number of challenges to the healthcare sector, as not only will some drugs work not at all or only poorly with certain people, of even greater concern is the possibility that some drugs may even prove to be toxic to certain individuals. However, the nature of medical research dictates that it is best to promote a treatment that isn’t too toxic and works for a reasonable number of people, instead of waiting until the science of exactly how and why the drug works is fully elucidated before using the drug. After all, for many conditions, we do not understand what causes disease in the first place, and the exact molecular mechanisms a new drug may trigger once administered may also be difficult to unravel.

Despite the best efforts of the pharmaceutical industry, even approved drugs often have known (and unknown) side effects, and there is a trade off between the nature of the disease under consideration, the effectiveness of the drug in a clinical setting and the type of side effects that are acceptable under the circumstances. This is part of the risk/benefit assessment made by regulatory agencies based on safety, quality and efficacy. As the recent withdrawal from the market of Merck’s Vioxx pain killer drug illustrates, the formal regulatory response to documented evidence of the elevated risk of heart attacks in patients was to act decisively – the drugs came off the shelves. This is to be expected; after all, the regulatory agencies operate to maintain confidence in the marketing approvals system, and there is high profile and costly litigation to be expected where a drug turns out to have contributed to the death of patients.

But what if the unpleasant or toxic side effects of a drug only actually affected a certain part of the population? If it were possible to identify which patients will receive the benefit of the treatment but not suffer the worst side effects, then perhaps a number of existing drugs could come back off the shelves. New drugs could be targeted at specific individuals, and people would not receive prescriptions for drugs that, due to their particular genotype, aren’t any better than a placebo. This is the promise of pharmacogenomics and pharmacogenetics.

Pharmacogenetics is a term often used to describe, amongst other things, the study of our individual genetic variations and their impact on drug efficacy and toxicity. Pharmacogenomics relates to the wider study of genetic information and how it relates to the origins of diseases as well as drug development, although the terms pharmacogenomics and pharmacogenetics are often used interchangeably.

The European Regulatory Regime

In setting out its Road Map to 20101, The European Medicines Agency (EMEA) describes Pharmacogenetics as an ‘emerging technology’. As is typical of promising but still-developing technologies, the regulatory framework validating the results of the pharmacogenetic healthcare establishment is itself simultaneously evolving. Indeed, only in the last few years has the EMEA started to focus on how genetic data can be applied as a factor in determining whether regulatory approval for new or existing pharmaceuticals should be given or maintained.

The EMEA has adopted a position paper2 on terminology explaining what pharmacogenetics and pharmacogenomics are. The European Medicines Agency (EMEA) describes Pharmacogenetics as the study of interindividual variations in DNA sequence related to drug response and Pharmacogenomics as the study of the variability of the expression of individual genes relevant to disease susceptibility as well as drug response at cellular, tissue, individual or population level. It is further stated that the Pharmacogenomics is a term broadly applicable to drug design, discovery and clinical development, although the paper itself acknowledges that the terminology in common usage is variable and inconsistent.

Importantly, the position paper also deals with the various options relating to the manner in which patient information may handled and retained following clinical trials. This highlights a concern of certain patient groups and ethics observers; the rules concerning the collection, analysis and storage of individuals’ genetic information. Of course, pharmacogenetics cannot properly advance without knowledge of the genetic data from people taking part in clinical trials, and concerns about data protection may ultimately determine how effectively a future drug designed with pharmacogenetic considerations in mind will be prescribed. The EMEA has published a leaflet3 aimed at volunteers participating in clinical trials setting out various ways in which genetic data may be linked to clinical data, which touches on the potential conflict between maintaining high levels of privacy/data protection and the ability to provide a benefit to participants in the clinical trial based on that data.

The Pharmacogenetics Working Party

The EMEA has also set up a Pharmacogenetics Working Party, part of the Pharmacogenetics Working Group (‘PWG’), and the objectives and rules of procedures of the working party have been set down4. In particular, a wider objective of the PWG is to provide the CHMP Committee with guidelines for the preparation and assessment of future pharmacogenetic elements of the regulatory submissions. Accordingly, the input of the PWG and its working party is likely to have a significant impact on the way the regulatory approvals process develops to deal with the inclusion of pharmacogenetic portfolio data.

An obvious area of concern for the pharmaceutical industry is the manner in which pharmacogenetic data will be considered by the relevant regulatory bodies. The quality and reliability of scientific data are often dependant upon more recent technologies, for example, data processed by computer analysis of hybridisation results arising from multiple microarray screenings. Pharmacogenetic information of gene expression studies is typically complex, and rarely gives a black and white answer, although this isn’t surprising bearing in mind that numerous genes may be responsible for determining particular drug interactions.

Further, if a pharmaceutical company has only acquired a limited amount of pharmacogenetic data, must it always supply such data to the regulatory authorities, whether it may wish to rely on the data for regulatory approval or not? What if the data is only available from a sub-population, or more seriously, if that data tentatively indicates that a pharmacogenetic marker indicates that toxicity may be a problem when a given drug is administered? How much weight will be given to such data by the regulatory body? When can a genetic marker be regarded as an established "biomarker" for a given drug reaction?

Inevitably, we do not yet have many answers to these questions, but the EMEA has published a proposal to allow applicants to meet with the Pharmacogenetic Working Party for the purpose of exchanging information and addressing the likely regulatory hurdles, before new guidelines and laws are set down. In March 2005, the EMEA published a Guideline on Pharmacogenetics Briefing Meetings5. This document sets out the manner in which the EMEA would like the pharmaceutical industry to involve itself in the development of the regulatory framework via the Pharmacogenetic Working Party.

Under the proposed guidelines, a pharmaceutical company has the opportunity to discuss various aspects of pharmacogenetics with the expert members of the Pharmacogenetic Working Party. Most importantly, the meetings are informal, and the data presented to the Pharmacogenetic Working Party regarding a current drug in development will not be formally subject to regulatory pre-assessment. Further, the Pharmacogenetic Working Party is likely to discuss with the drug sponsor various technical and regulatory issues that might cause difficulties or concerns during the initial selection of drug targets and throughout the regulatory clinical trials procedures. Accordingly, pharmaceutical companies may wish to consider such an informal forum as an important route to both refining the manner in which they gather and present future pharmacogenetic data for regulatory purposes, but also to air their concerns, and even influence the way in which the regulatory regime will address the arrival of new and complex pharmacogenetic data in the approvals process. The guideline also notes that such informal meetings regarding new drug data should take place prior to the applicant having made contact with the actual regulators, including national agencies or the CHMP.

Format of Submissions of Pharmacogenetic Data

The guideline in its current form sets out further detail both on how the Pharmacogenetic Working Party envisages meetings between it and drug sponsors proceeding, and additionally on the format of submission of pharmacogenetic data. This latter aspect of the proposal may be of particular interest to pharmaceutical companies, as the scale of these requirements may form the basis of what will actually be required under future regulatory laws. If these requirements are simply too onerous, pharmaceutical companies may well be put off carrying out pharmacogenetic based trials and research, perhaps until forced to do so. However, it is possible to envisage that in the future, for reasons of safety perhaps more than efficacy, all new drugs applications will require a pharmacogenetic section included in their marketing approval application, in addition to the current requirements of a portfolio containing physicochemical/biological/microbiological, toxicological & pharmaceutical and clinical trials data.

The EMEA is inviting comments on the current draft guideline by 30 September 2005.

Footnotes

1. EMEA/H/34163/03/Final ‘The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future’

2. EMEA/CPMP/3070/01 ‘Position Paper on Terminology in Pharmacogenetics’

3. EMEA/3842/04/Final ‘Understanding the terminology used in pharmacogenetics’

4. EMEA/CHMP/101592/04 Mandate, Objectives and Rules of Procedure for the CHMP Pharmacogenetics Working Party

5. EMEA/CHMP/6806/05

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.